AKTivate Therapeutics, Virax deal

Virax will acquire AKTivate Therapeutics for $300,000 in cash and 134 million shares up front valued at A$1.3

Read the full 185 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE